Years af­ter bank­rupt­cy, Den­dreon adds a con­tract man­u­fac­tur­ing wing

When CEO Ja­son O’Neill came aboard Den­dreon just a year ago, he saw that the com­pa­ny was in a unique po­si­tion: It oc­cu­pied a rare space as one of the few end-to-end providers of cell ther­a­py man­u­fac­tur­ing ser­vices. And if it were to add a di­vi­sion of con­tract man­u­fac­tur­ing arm to its op­er­a­tions, it would po­si­tion it­self as one of just four US com­pa­nies that are do­ing so.

So with that, the Seal Beach, Cal­i­for­nia-based bio­phar­ma com­pa­ny has es­tab­lished a con­tract man­u­fac­tur­ing and ser­vices di­vi­sion to bring late-stage clin­i­cal projects through to the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER